Spinal muscular atrophy: a motor neuron disorder or a multi‐organ disease?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Anatomy

• Publication date

  2014-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/joa.12083PMID 23876144PMCID PMC3867883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Spinal Muscular Atrophy: New Findings for an Old Pathology

  2013cited by this paper
• Defects in neuromuscular junction remodelling in the Smn(2B/-) mouse model of spinal muscular atrophy.

  2013cited by this paper
• Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice.

  2013cited by this paper
• Diabetic Ketoacidosis in an Adult Patient With Spinal Muscular Atrophy Type II

  2013cited by this paper
• Temporal requirement for SMN in motoneuron development.

  2013cited by this paper
• Synaptic defects in type I spinal muscular atrophy in human development

  2013cited by this paper
• At the "junction" of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression.

  2013cited by this paper
• Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy.

  2012cited by this paper
• A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology.

  2012cited by this paper
• Density, calibre and ramification of muscle capillaries are altered in a mouse model of severe spinal muscular atrophy.

  2012cited by this paper
• A cell-autonomous defect in skeletal muscle satellite cells expressing low levels of survival of motor neuron protein.

  2012cited by this paper
• Survival Motor Neuron Protein in Motor Neurons Determines Synaptic Integrity in Spinal Muscular Atrophy

  2012cited by this paper
• Evaluation of fetal nuchal translucency in 98 pregnancies at risk for severe spinal muscular atrophy: possible relevance of the SMN2 copy number

  2012cited by this paper
• Decreasing Disease Severity in Symptomatic, Smn −/−;SMN2 +/+, Spinal Muscular Atrophy Mice Following scAAV9-SMN Delivery

  2012cited by this paper
• SMN-inducing compounds for the treatment of spinal muscular atrophy.

  2012cited by this paper
• Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy

  2012cited by this paper
• New Therapeutic Approaches to Spinal Muscular Atrophy

  2012cited by this paper
• Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy.

  2012cited by this paper
• Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585

  2012influential reference
• Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy.

  2012cited by this paper
• Motor Neuron Rescue in Spinal Muscular Atrophy Mice Demonstrates That Sensory-Motor Defects Are a Consequence, Not a Cause, of Motor Neuron Dysfunction

  2012influential reference
• Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy.

  2012cited by this paper
• Drug treatment for spinal muscular atrophy types II and III.

  2012cited by this paper
• Glucose metabolism and pancreatic defects in spinal muscular atrophy

  2012cited by this paper
• Abnormal fatty acid metabolism in spinal muscular atrophy may predispose to perioperative risks.

  2012cited by this paper
• Perfluorodecalin lavage of a longstanding lung atelectasis in a child with spinal muscle atrophy

  2012cited by this paper
• An SMN-dependent U12 splicing event essential for motor circuit function.

  2012cited by this paper
• A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.

  2012cited by this paper
• Therapeutic strategies for the treatment of spinal muscular atrophy.

  2012cited by this paper
• Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model

  2011cited by this paper
• Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons.

  2011cited by this paper
• Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy.

  2011cited by this paper
• Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

  2011cited by this paper
• Cardiac involvement in patients with Spinal Muscular Atrophies

  2011cited by this paper
• Reversible molecular pathology of skeletal muscle in spinal muscular atrophy.

  2011cited by this paper
• Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy

  2011cited by this paper
• Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens

  2011cited by this paper
• Temporal requirement for high SMN expression in SMA mice.

  2011influential reference
• New insights into the pathogenesis of spinal muscular atrophy.

  2011cited by this paper
• SMN Requirement for Synaptic Vesicle, Active Zone and Microtubule Postnatal Organization in Motor Nerve Terminals

  2011cited by this paper
• Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.

  2011cited by this paper
• Faculty Opinions recommendation of Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.

  2011influential reference
• Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway.

  2011cited by this paper
• Increased IGF-1 in muscle modulates the phenotype of severe SMA mice.

  2011cited by this paper
• Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy.

  2011cited by this paper
• Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy

  2010cited by this paper
• Synaptic Defects in the Spinal and Neuromuscular Circuitry in a Mouse Model of Spinal Muscular Atrophy

  2010influential reference
• Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model.

  2010cited by this paper
• Reduced Survival of Motor Neuron (SMN) Protein in Motor Neuronal Progenitors Functions Cell Autonomously to Cause Spinal Muscular Atrophy in Model Mice Expressing the Human Centromeric (SMN2) Gene

  2010cited by this paper
• Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

  2010cited by this paper
• Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy.

  2010cited by this paper
• Neurodevelopmental consequences of Smn depletion in a mouse model of spinal muscular atrophy

  2010cited by this paper
• Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy.

  2010cited by this paper
• Review: Neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy

  2010cited by this paper
• SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.

  2010cited by this paper
• therapeutic strategies

  2010cited by this paper
• Cardiac defects contribute to the pathology of spinal muscular atrophy models.

  2010cited by this paper
• Altered Intracellular Ca2+ Homeostasis in Nerve Terminals of Severe Spinal Muscular Atrophy Mice

  2010cited by this paper
• SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy.

  2010cited by this paper
• Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice.

  2010cited by this paper
• Therapeutics that directly increase SMN expression to treat spinal muscular atrophy.

  2010cited by this paper
• Digital necroses and vascular thrombosis in severe spinal muscular atrophy

  2010cited by this paper
• Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery.

  2010influential reference
• CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.

  2010cited by this paper
• Treatment and complications in flaccid neuromuscular scoliosis (Duchenne muscular dystrophy and spinal muscular atrophy) with posterior-only pedicle screw instrumentation

  2010cited by this paper
• An antisense microwalk reveals critical role of an intronic position linked to a unique long-distance interaction in pre-mRNA splicing.

  2010cited by this paper
• Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

  2010cited by this paper
• Drug treatment for spinal muscular atrophy types II and III.

  2009cited by this paper
• The Developmental Pattern of Myotubes in Spinal Muscular Atrophy Indicates Prenatal Delay of Muscle Maturation

  2009cited by this paper
• A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy

  2009cited by this paper
• An autopsy case of spinal muscular atrophy type III (Kugelberg‐Welander disease)

  2009cited by this paper
• Genotype–phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling

  2009cited by this paper
• Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

  2009cited by this paper
• Vascular perfusion abnormalities in infants with spinal muscular atrophy.

  2009cited by this paper
• Impaired Synaptic Vesicle Release and Immaturity of Neuromuscular Junctions in Spinal Muscular Atrophy Mice

  2009cited by this paper
• Emerging treatment options for spinal muscular atrophy

  2009cited by this paper
• Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy.

  2008cited by this paper
• Embryonic motor axon development in the severe SMA mouse.

  2008cited by this paper
• Spinal muscular atrophy.

  2008cited by this paper
• Congenital heart defects in spinal muscular atrophy type I: A clinical report of two siblings and a review of the literature

  2008cited by this paper
• Congenital heart disease is a feature of severe infantile spinal muscular atrophy

  2008cited by this paper
• Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect.

  2008influential reference
• Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy.

  2008influential reference
• Energy metabolism in heart failure and remodelling.

  2008cited by this paper
• [Type I spinal atrophy (Werdnig-Hoffman disease). Case report].

  2007cited by this paper
• Long-Term Survival in Werdnig–Hoffmann Disease

  2007cited by this paper
• Mutations of the LMNA gene can mimic autosomal dominant proximal spinal muscular atrophy

  2007cited by this paper
• Medical Considerations of Long-Term Survival of Werdnig–Hoffmann Disease

  2007influential reference
• Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.

  2007cited by this paper
• Neonatal Spinal Muscular Atrophy Type 1 With Bone Fractures and Heart Defect

  2007cited by this paper
• Motor Neuron Degeneration in a 20-Week Male Fetus: Spinal Muscular Atrophy Type 0

  2007cited by this paper
• Atrofia espinal tipo I (síndrome de Werdnig-Hoffmann).Reporte de un caso

  2007cited by this paper
• The changing natural history of spinal muscular atrophy type 1

  2007cited by this paper
• Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophy

  2007cited by this paper
• Spinal muscular atrophy: from gene to therapy.

  2006cited by this paper
• Distinct and overlapping alterations in motor and sensory neurons in a mouse model of spinal muscular atrophy.

  2006cited by this paper
• Neural crest stem and progenitor cells.

  2006cited by this paper
• Implication of Fetal SMN2 Expression in Type I SMA Pathogenesis: Protection or Pathological Gain of Function?

  2005cited by this paper
• An infant with hypoplastic left heart syndrome and spinal muscular atrophy.

  2005cited by this paper
• Reduced U snRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy.

  2005cited by this paper

• Lymphoid Organ Architecture and Hematopoiesis Disruption in Spinal Muscular Atrophy: Therapeutic Rescue by SMN Restoration

  2026cites this paper
• Changes in the cortical GABAergic inhibitory system in a Spinal Muscular Atrophy mouse model.

  2026cites this paper
• Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway

  2026cites this paper
• Impaired renal function in patients with spinal muscular atrophy: A longitudinal cohort study.

  2026cites this paper
• Skeletal muscle in spinal muscular atrophy: Critical insights from pathogenesis to therapeutic strategies.

  2026cites this paper
• Cerebellar defects are a primary pathology in mouse models of spinal muscular atrophy

  2025cites this paper
• Impact of liver-specific survival motor neuron (SMN) depletion on central nervous system and peripheral tissue pathology

  2025cites this paper
• Biomarkers of immune dysregulation and posttreatment inflammation in spinal muscular atrophy.

  2025cites this paper
• Analysis of Eye Movements in Adults with Spinal Muscular Atrophy

  2025cites this paper
• 10H-phenothiazine exerts beneficial effects in spinal muscular atrophy in vitro and in vivo models

  2025cites this paper
• Beyond motor neurons: autonomic dysfunction and ECG findings in adults with 5q-spinal muscular atrophy

  2025cites this paper
• Dysregulated balance of D- and L-amino acids modulating glutamatergic neurotransmission in severe spinal muscular atrophy

  2025cites this paper
• Clinical Application of Risdiplam in 5q Spinal Muscular Atrophy: A Narrative Review.

  2025cites this paper
• Real-world data on spinal muscular atrophy in Spain: Insights from over 500 individuals in the CuidAME project

  2025cites this paper
• Sensory Nerve Action Potential Analysis in a Cohort of Patients With Spinal Muscular Atrophy Aged 12 Years and Older

  2025cites this paper
• [Nusinersen combined with risdiplam for the treatment of spinal muscular atrophy: a case series of 10 patients and literature review].

  2025cites this paper
• Comorbidities in spinal muscular atrophy and their impact on the course of the underlying disease: a real-life observational study

  2025cites this paper
• Pilocytic Astrocytoma in a Child with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec.

  2025cites this paper
• Genomic stress drives activation of interferon signaling and innate immune pathways during SMA Type II myoblasts differentiation

  2025cites this paper
• Spinal muscular atrophy clinical aspects – review article

  2025cites this paper
• Echocardiographic evaluation of left ventricular function in children with spinal muscular atrophy before and after nusinersen treatment.

  2025cites this paper
• Ketosis-prone Diabetes as a Presentation of New-onset Diabetes in a Patient With Spinal Muscular Atrophy Type III

  2025cites this paper
• The Impact of Comorbidities and Motor Impairment on the Quality of Life of Patients with Spinal Muscular Atrophy: A Case–Control Study

  2024cites this paper
• A perspective: neuraxial therapeutics in pain management: now and future

  2024cites this paper
• Autophagy in spinal muscular atrophy: from pathogenic mechanisms to therapeutic approaches

  2024cites this paper
• Cadmium Neurotoxicity: Insights into Behavioral Effect and Neurodegenerative Diseases.

  2024cites this paper
• Metabolic syndrome is common in adults with 5q‐spinal muscular atrophy and impacts quality of life and fatigue

  2024cites this paper
• The systemic complexity of a monogenic disease: the molecular network of spinal muscular atrophy.

  2024cites this paper
• Coexistence of SMA Type I with Citrate Transporter Deficiency Disorder: A Case Report

  2024cites this paper
• Longitudinal data collection in pediatric and adult patients with 5q spinal muscular atrophy in Latin America: LATAM RegistrAME study - a clinical registry study protocol

  2024cites this paper
• Optimized MLPA workflow for spinal muscular atrophy diagnosis: identification of a novel variant, NC_000005.10:g.(70919941_70927324)del in isolated exon 1 of SMN1 gene through long-range PCR

  2024cites this paper
• Common complications in spinal muscular atrophy (SMA) type 1 after nusinersen treatment.

  2024cites this paper
• Brain magnetic resonance imaging of patients with spinal muscular atrophy type 2 and 3

  2024cites this paper
• Fatigue in Spinal Muscular Atrophy: a fundamental open issue

  2024cites this paper
• The organoid modeling approach to understanding the mechanisms underlying neurodegeneration: A comprehensive review.

  2024cites this paper
• Cognitive impairment in children with 5q-associated spinal muscular atrophy type 1: two case reports and the review of the literature

  2024cites this paper
• Paradoxical metabolic acidosis after vomiting in children with spinal muscular atrophy: A report of 9 patients.

  2024cites this paper
• Neurophysiological Evaluation of Autonomic Dysfunction in Spinal Muscular Atrophy: A Case‐Control Study

  2024cites this paper
• Sensory dysfunction in SMA type 2 and 3 - adaptive mechanism or concomitant target of damage?

  2024cites this paper
• Dysregulated balance of D- and L-amino acids modulating glutamatergic neurotransmission in severe spinal muscular atrophy

  2024cites this paper
• Modern approaches to the treatment of spinal muscular atrophy

  2023cites this paper
• "Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists": reply.

  2023cites this paper
• Unveiling the Genetic Tapestry: Rare Disease Genomics of Spinal Muscular Atrophy and Phenylketonuria Proteins

  2023cites this paper
• SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy

  2023cites this paper
• Review of cardiac safety in onasemnogene abeparvovec gene replacement therapy: translation from preclinical to clinical findings

  2023cites this paper
• Current and emerging targeted therapies for spinal muscular atrophy

  2023cites this paper
• Current Development in Treatment of Spinal Muscular Atrophy

  2023cites this paper
• Biomarkers in 5q-associated spinal muscular atrophy—a narrative review

  2023cites this paper
• SMN Deficiency Destabilizes ABCA1 Expression in Human Fibroblasts: Novel Insights in Pathophysiology of Spinal Muscular Atrophy

  2023cites this paper
• Children With Type 1 Spinal Muscular Atrophy Are at Increased Risk for Nephrolithiasis.

  2023cites this paper
• [Modern principles of therapy for patients with spinal muscular atrophy].

  2023cites this paper
• Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice

  2023cites this paper
• The RNA-Binding Protein SMN as a Novel Player in Laryngeal Squamous Cell Carcinoma

  2023cites this paper
• Motor fiber function in spinal muscular atrophy—analysis of conduction velocity distribution

  2023cites this paper
• Refinement of Intrathecal catheter design to enhance neuraxial distribution.

  2023cites this paper
• The SMN Complex at the Crossroad between RNA Metabolism and Neurodegeneration

  2023cites this paper
• Spinal muscular atrophy in childhood - actual treatment options 

  2022cites this paper
• Microvasculopathy in spinal muscular atrophy is driven by a reversible autonomous endothelial cell defect

  2022cites this paper
• Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)

  2022cites this paper
• Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model

  2022cites this paper
• The alteration of left ventricular strain in later-onset spinal muscular atrophy children

  2022cites this paper
• Peripheral circulation disturbances in two consecutive children with spinal muscular atrophy and literature review

  2022cites this paper
• Suppression of the necroptotic cell death pathways improves survival in Smn2B/− mice

  2022cites this paper
• Disease Burden of Spinal Muscular Atrophy: A Comparative Cohort Study Using Insurance Claims Data in the USA

  2022cites this paper
• A Historical Review of Brain Drug Delivery

  2022cites this paper
• Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins.

  2022cites this paper
• Structure and function analysis of Sam68 and hnRNP A1 synergy in the exclusion of exon 7 from SMN2 transcripts

  2022cites this paper
• Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.

  2022cites this paper
• Cognitive profiles and clinical factors in type III spinal muscular atrophy: A preliminary study.

  2022cites this paper
• Motor Unit and Capillary Recruitment During Fatiguing Arm-Cycling Exercise in Spinal Muscular Atrophy Types 3 and 4

  2022cites this paper
• 264th ENMC International Workshop: Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th - 21st 2021.

  2022cites this paper
• Protein Network Analysis Reveals a Functional Connectivity of Dysregulated Processes in ALS and SMA

  2022cites this paper
• GGC repeat expansions in NOTCH2NLC causing a phenotype of lower motor neuron syndrome

  2022cites this paper
• R-loop Mediated DNA Damage and Impaired DNA Repair in Spinal Muscular Atrophy

  2022cites this paper
• Management of Spinal Muscular Atrophy in the Adult Population

  2022cites this paper
• Is it now time to screen your baby for spinomuscular muscular atrophy?

  2022cites this paper
• Motor unit reserve capacity in spinal muscular atrophy during fatiguing endurance performance.

  2021cites this paper
• The Relationship between Body Composition, Fatty Acid Metabolism and Diet in Spinal Muscular Atrophy

  2021cites this paper
• Glucose and lipid metabolism disorders in children and adolescents with spinal muscular atrophy types 2 and 3.

  2021cites this paper
• Fine-Tuning of mTOR mRNA and Nucleolin Complexes by SMN

  2021cites this paper
• Cognitive Impairment in Adult Patients with 5q-Associated Spinal Muscular Atrophy

  2021cites this paper
• Magnetic resonance reveals mitochondrial dysfunction and muscle remodelling in spinal muscular atrophy

  2021cites this paper
• Activation of Muscle-Specific Kinase (MuSK) Reduces Neuromuscular Defects in the Delta7 Mouse Model of Spinal Muscular Atrophy (SMA)

  2021cites this paper
• Top 100 most cited journal articles in anatomy

  2021cites this paper
• Age‐related sensory neuropathy in patients with spinal muscular atrophy type 1

  2021cites this paper
• Nutritional, Gastrointestinal and Endo-Metabolic Challenges in the Management of Children with Spinal Muscular Atrophy Type 1

  2021cites this paper
• Spinal Muscular Atrophy.

  2021cites this paper
• Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients

  2021cites this paper
• Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment

  2021cites this paper
• Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development

  2021cites this paper
• Modern View of SMA: Present and Future (Literature Review)

  2021cites this paper
• Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1

  2021cites this paper
• In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy

  2021cites this paper
• Ultrastructural characterization of peripheral denervation in a mouse model of Type III spinal muscular atrophy

  2021cites this paper
• Skin necrosis in spinal muscular atrophy: Case report and review of the literature.

  2021cites this paper
• [Stress induced ketoacidosis in spinal muscular atrophy. Report of one case].

  2020cites this paper
• Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study

  2020cites this paper
• Metabolic and Nutritional Issues Associated with Spinal Muscular Atrophy

  2020cites this paper
• Cardiac findings in pediatric patients with spinal muscular atrophy types 2 and 3

  2020cites this paper
• Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.

  2020cites this paper